Neoadjuvant personalized cancer vaccines: the final frontier?

References

• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):1–19. doi: 10.3390/cancers12030738
   Web of Science ®Google Scholar
• Merck and moderna initiate phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA® (pembrolizumab) for adjuvant treatment of patients with resected high-risk (stage IIB-IV) melanoma [Internet]. Available from: https://www.merck.com/news/merck-and-moderna-initiate-phase-3-study-evaluating-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-high-riskstage-iib-iv-melanom/
   Google Scholar
• Shemesh CS, Hsu JC, Hosseini I, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555–570. doi: 10.1016/j.ymthe.2020.09.038
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911–926.
   PubMedGoogle Scholar
• Carreno BM, Magrini V, Becker-Hapak M, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–808. doi: 10.1126/science.aaa3828
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226. doi: 10.1038/nature23003
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221. doi: 10.1038/nature22991
   PubMed Web of Science ®Google Scholar
• Khattak A, Carlino M, Meniawy T, et al. Abstract CT001: a personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: efficacy and safety results from the randomized, open-label phase 2 mRNA-4157-P201/Keynote-942 trial. Cancer Res. 2023;83(8_Supplement):CT001. doi: 10.1158/1538-7445.AM2023-CT001
   Google Scholar
• Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–239. doi: 10.1038/s41586-018-0792-9
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell. 2020;183(2):347–362.e24. doi: 10.1016/j.cell.2020.08.053
   PubMed Web of Science ®Google Scholar
• Gane E, Yarchoan M, Marron T, et al. 693 personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC). J Immunother Cancer. 2022;10:A724.
   Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150. doi: 10.1038/s41586-023-06063-y
   PubMed Web of Science ®Google Scholar
• Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med. 2023;29(10):2379–2380. doi: 10.1038/d41591-023-00072-0
   PubMedGoogle Scholar
• Gubin MM, Vesely MD. Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res. 2022;28(18):3917–3928.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56–71. doi: 10.1111/imr.12132
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RPT, et al. Randomized selection design trial evaluating CD8±enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31:2152–2159. doi: 10.1200/JCO.2012.46.6441
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi: 10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi: 10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Massari F, Di Nunno V, Cubelli M, et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev. 2018;64:11–20. doi: 10.1016/j.ctrv.2017.12.007
   PubMed Web of Science ®Google Scholar
• Richard G, Princiotta MF, Bridon D, et al. Neoantigen-based personalized cancer vaccines, the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2021;21:173–184. doi: 10.1080/14760584.2022.2012456
   Google Scholar
• Bilusic M, Gulley JL. Neoadjuvant Immunotherapy: An Evolving Paradigm Shift? J Natl Cancer Inst. 2021;113(7):799–800. doi: 10.1093/jnci/djaa217
   PubMedGoogle Scholar
• Mittendorf EA, Burgers F, Haanen J, et al. Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease. Am Soc Clin Oncol Educ B. 2022;(42):189–203. doi: 10.1200/EDBK_349411
   Google Scholar
• Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256–263. doi: 10.1038/s41591-020-01211-7
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–960. doi: 10.1016/S1470-2045(19)30151-2
   PubMed Web of Science ®Google Scholar
• Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the international neoadjuvant melanoma consortium (INMC). Nat Med. 2021;27(2):301–309. doi: 10.1038/s41591-020-01188-3
   PubMed Web of Science ®Google Scholar
• Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813–823. doi: 10.1056/NEJMoa2211437
   PubMed Web of Science ®Google Scholar
• Kasztura M, Richard A, Bempong NE, et al. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health. 2019;64:1261–1271. doi: 10.1007/s00038-019-01298-x
   PubMed Web of Science ®Google Scholar
• Vellekoop H, Versteegh M, Huygens S, et al. The net benefit of personalized medicine: a systematic literature review and regression analysis. Value Heal. 2022;25(8):1428–1438. doi: 10.1016/j.jval.2022.01.006
   PubMed Web of Science ®Google Scholar
• Bourgeois-Daigneault M-C, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10(422):10. doi: 10.1126/scitranslmed.aao1641
   Web of Science ®Google Scholar
• Samson A, Scott KJ, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10(422):10. doi: 10.1126/scitranslmed.aam7577
   Web of Science ®Google Scholar
• Li R, Zhang J, Gilbert SM, et al. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021;18(9):543–555. doi: 10.1038/s41585-021-00483-z
   PubMed Web of Science ®Google Scholar
• Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–1506. doi: 10.1038/s41591-018-0146-z
   PubMed Web of Science ®Google Scholar
• Benitez R, Godelaine D, Lopez-Nevot MA, et al. Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 1998;52(6):520–529. doi: 10.1111/j.1399-0039.1998.tb03082.x
   PubMedGoogle Scholar
• Tran E, Robbins PF, Lu Y-C, et al. T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–2262. doi: 10.1056/NEJMoa1609279
   PubMed Web of Science ®Google Scholar
• Perales R, Perales-Puchalt A, Bartha G, et al. 692 circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab). J Immunother Cancer. 2022;10:A723.
   Google Scholar
• Carlino MS, Khattak A, Weber JS, et al. Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab. J Clin Oncol. 2023;41(17_suppl):LBA9515. doi: 10.1200/JCO.2023.41.17_suppl.LBA9515
   Web of Science ®Google Scholar
• Williamson CW, Sherer MV, Zamarin D, et al. Immunotherapy and radiation therapy sequencing: state of the data on timing, efficacy, and safety. Cancer. 2021;127:1553–1567. doi: 10.1002/cncr.33424
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–235. doi: 10.1093/annonc/mdy551
   PubMed Web of Science ®Google Scholar
• Collins JM, Redman JM, Gulley JL. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Rev Vaccines. 2018;17(8):697–705. doi: 10.1080/14760584.2018.1506332
   PubMed Web of Science ®Google Scholar
• Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20(9):1231–1243. doi: 10.1038/s41590-019-0441-y
   PubMed Web of Science ®Google Scholar
• Vavolizza RD, Petroni GR, Mauldin IS, et al. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). J Immunother Cancer. 2022;10(9):1–14. doi: 10.1136/jitc-2022-005424
   Web of Science ®Google Scholar
• McNeel DG, Eickhoff JC, Wargowski E, et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9(39):25586–25596. doi: 10.18632/oncotarget.25387
   PubMedGoogle Scholar
• Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934–949.e15. doi: 10.1016/j.cell.2017.09.028
   PubMed Web of Science ®Google Scholar
• van der Auwera G, O’Connor BD. Genomics in the cloud: using docker, GATK, and WDL in terra. Sebastopol, CA: O’Reilly Media, Incorporated; 2020. https://www.oreilly.com/library/view/genomics-in-the/9781491975183/
   Google Scholar
• Lee H, Kingsford CK. Kourami: graph-guided assembly for novel human leukocyte antigen allele discovery. Genome Biol. 2018;19(1):1–16. doi: 10.1186/s13059-018-1388-2
   PubMedGoogle Scholar
• Benjamin D, Sato T, Cibulskis K, et al. Calling somatic SNVs and indels with Mutect2. bioRxiv. 2019;861054:1–8. https://www.biorxiv.org/content/10.1101/861054v1
   Google Scholar
• Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591–594. doi: 10.1038/s41592-018-0051-x
   PubMed Web of Science ®Google Scholar
• McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):1–14. doi: 10.1186/s13059-016-0974-4
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, Terry F, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using Immunoinformatics tools. Front Immunol. 2020;11:1–13. doi: 10.3389/fimmu.2020.00442
   PubMed Web of Science ®Google Scholar
• Losikoff PT, Mishra S, Terry F, et al. HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. J Hepatol. 2015;62(1):48–55. doi: 10.1016/j.jhep.2014.08.026
   PubMed Web of Science ®Google Scholar
• Liu R, Moise L, Tassone R, et al. H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce treg-mediated tolerance. Hum Vaccines Immunother. 2015;11(9):2241–2252. doi: 10.1080/21645515.2015.1052197
   PubMed Web of Science ®Google Scholar
• Dembele M, Tao S, Massoud AH, et al. Tregitopes improve asthma by promoting highly suppressive and Antigen-Specific Tregs. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.634509
   Web of Science ®Google Scholar
• De Groot AS, Rosenberg AS, Miah SMS, et al. Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clin Immunol. 2021;224:108661. doi: 10.1016/j.clim.2020.108661
   PubMed Web of Science ®Google Scholar
• Miah SMS, Lelias S, Gutierrez AH, et al. A SARS-CoV-2 NSP7 homolog of a treg epitope suppresses CD4+ and CD8+ T cell memory responses. Front Immunol. 2023;14:14. doi: 10.3389/fimmu.2023.1290688
   Web of Science ®Google Scholar
• Wada Y, Nithichanon A, Nobusawa E, et al. A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Sci Rep. 2017;7(1):1283. doi: 10.1038/s41598-017-01372-5
   PubMedGoogle Scholar
• Jang H, Meyers LM, Boyle C, et al. Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge. Hum Vaccines Immunother. 2020;16(9):2042–2050. doi: 10.1080/21645515.2020.1793711
   PubMed Web of Science ®Google Scholar
• Khan S, Parrillo M, Gutierrez AH, et al. Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi. Hum Vaccines Immunother. 2020;16(2):214–227. doi: 10.1080/21645515.2018.1560772
   PubMed Web of Science ®Google Scholar
• Grinshtein N, Bridle B, Wan Y, et al. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res. 2009;69(9):3979–3985. doi: 10.1158/0008-5472.CAN-08-3385
   PubMed Web of Science ®Google Scholar
• Fisher SA, Cleaver A, Lakhiani DD, et al. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. J Transl Med. 2014;12(1):1–9. doi: 10.1186/s12967-014-0245-7
   PubMedGoogle Scholar
• Ogino H, Taylor JW, Nejo T, et al. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022;132(3):132. doi: 10.1172/JCI151239
   Web of Science ®Google Scholar
• Heumann T, Judkins C, Li K, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023;14(1):1–12. doi: 10.1038/s41467-023-39196-9
   PubMed Web of Science ®Google Scholar
• Gouglas D, Christodoulou M, Plotkin SA, et al. CEPI: driving progress toward epidemic preparedness and response. Epidemiol Rev. 2019;41:28–33. doi: 10.1093/epirev/mxz012
   PubMed Web of Science ®Google Scholar